CompletedNo phase
Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma
Key facts
- Who runs it
- Central Hospital, Nancy, France
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 11 people enrolled
- Started
- 1 Nov 2024
- Ended
- 25 Feb 2025
- Type of study
- Observational
- Treatments tested
- tumoral dosimetry by scintigraphy
- Record updated
- 25 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- patients treated for menigioma at nancy hospital
- patients who performed 3 scintigraphics exams during there treatment
Who cannot take part
- patients deprived of liberty
- patient who refused to collect data retrospectively
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.
The group in the trial
- Patients treated with 177Lu-DOTATATE for meningioma
Patients treated with 177Lu-DOTATATE for meningioma at the Nancy's hospital who met the treatment criteria of the Compassionate Prescribing Framework and received a scintigraphy at D1, D4 and D7 (± 1 day)
Treatment: tumoral dosimetry by scintigraphy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 25 June 2026